Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80,384 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Patient Clear all
Active, not recruiting Phase 2 Interventional

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

NCT03375307
View directory record Official record
Conditions
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Positron Emission Tomography
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
17
States / cities
Encinitas, California • Irvine, California • La Jolla, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 10, 2026, 5:15 PM EDT
Completed No phase listed Observational

Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes

NCT05233592
View directory record Official record
Conditions
Type 1 Diabetes, Diabetes Mellitus, Type 1
Interventions
CGM
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 10, 2026, 5:15 PM EDT
Terminated Phase 2 Interventional Results available

Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes

NCT04365400
View directory record Official record
Conditions
Hypertriglyceridemia, Type 2 Diabetes
Interventions
DS102, Placebo
Drug
Lead sponsor
Afimmune
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Cerritos, California • Huntington Park, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2023 · Synced Sep 10, 2026, 5:15 PM EDT
Approved For Marketing No phase listed Expanded access

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

NCT04452136
View directory record Official record
Conditions
Prostatic Neoplasms, Prostatic Diseases, Prostate Cancer, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68GA PSMA-HBED-CC
Drug
Lead sponsor
Jeanne Link
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Early Phase 1 Interventional

Oral Peanut Immunotherapy for Peanut Allergic Patients

NCT01891136
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut protein
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 10, 2026, 5:15 PM EDT
Completed No phase listed Observational Results available

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

NCT04460911
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Not applicable Interventional

Effects of L-Carnitine on Postprandial Clearance of Triglyceride-rich Lipoproteins in HIV Patients on HAART

NCT00386971
View directory record Official record
Conditions
Hyperlipidemia, HIV Infections
Interventions
L-carnitine, placebo
Dietary Supplement · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 5:15 PM EDT
Terminated Not applicable Interventional

A Comparison of Diabetes Group Education as Administered Through Telemedicine Versus as Administered in Person

NCT00629434
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
diabetes education via telemedicine, diabetes education in-person
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

NCT00743509
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cyclophosphamide and Sirolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 3 Interventional

TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions

NCT00371709
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
TAXUS Liberté-SR, TAXUS™ Express
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 10, 2026, 5:15 PM EDT
Withdrawn Phase 1 Interventional

Effects of Probiotics in Patients With Ulcerative Colitis

NCT00578799
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Kyo-Dophilus, placebo
Dietary Supplement
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Not applicable Interventional

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

NCT00005799
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Not applicable Interventional

Effects of Aerobic Exercise in Patients With Pre-diabetes

NCT01860599
View directory record Official record
Conditions
Prediabetes
Interventions
Exercise, Without exercise
Behavioral
Lead sponsor
Baystate Medical Center
Other
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699
View directory record Official record
Conditions
Major Depression, Temporal Lobe Epilepsy
Interventions
escitalopram, placebo
Drug
Lead sponsor
Conrad, Erich J., M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2011 · Synced Sep 10, 2026, 5:15 PM EDT
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Family Intervention for Chinese Americans With Type 2 Diabetes

NCT04108299
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Wait-list control group, SMS intervention
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

A Study of Tor Kinase Inhibitor in Advanced Tumors

NCT00731263
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD8055
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT

NCT00460421
View directory record Official record
Conditions
Leukemia
Interventions
Palifermin, Total Body irradiation, Chemotherapy
Drug · Radiation
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
1 Year to 16 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
7
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Not applicable Interventional

Endometrial Injury and in Vitro Fertilization Outcomes

NCT02153814
View directory record Official record
Conditions
Infertility
Interventions
Endometrial Scratch, Sham procedure
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 10, 2026, 5:15 PM EDT
Recruiting No phase listed Observational

The Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer

NCT07622914
View directory record Official record
Conditions
Head and Neck Cancers
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 1 Interventional

Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents

NCT00790816
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib in combination with an anti-cancer agent, Lapatinib, Lapatinib in combination with an anti-cancer agent as specified by parent protocol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
15
States / cities
Scottsdale, Arizona • Tucson, Arizona • Santa Monica, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 10, 2026, 5:15 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With Retinoblastoma

NCT00004006
View directory record Official record
Conditions
Retinoblastoma
Interventions
filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, autologous bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 15 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Sep 10, 2026, 5:15 PM EDT
Recruiting Not applicable Interventional

TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections

NCT06637904
View directory record Official record
Conditions
Sepsis, Infections, Tachycardia, Fever
Interventions
TriVerity Test
Diagnostic Test
Lead sponsor
Inflammatix
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Peoria, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Sep 10, 2026, 5:15 PM EDT
Not listed Phase 2 Interventional

Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

NCT00006084
View directory record Official record
Conditions
Leukemia
Interventions
lintuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 10, 2026, 5:15 PM EDT